View More Recent Stories

Jul 5, 2023 08:00AM Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vagino
Jul 5, 2023 06:30AM REPEAT/Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
Jul 3, 2023 05:50AM Organon (OGN) and Samsung Bioepis Launch HADLIMA in the US
Jul 1, 2023 06:30AM Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
Jun 27, 2023 07:30AM Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals
Jun 7, 2023 07:30AM Organon and CAF, Development Bank of Latin America, Launch First-of-Its-Kind Collaboration to Increase Sustainable Financing in Women’s Health
May 4, 2023 07:30AM Organon Reports Results for the First Quarter Ended March 31, 2023
Apr 20, 2023 07:30AM Organon To Report First Quarter and Host Conference Call on May 4, 2023
Mar 7, 2023 07:00AM Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
Feb 16, 2023 07:30AM Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2022
Feb 13, 2023 06:43AM Ahead of International Women's Day, Organon Calls for Recognition of the Impacts of Underinvesting in Women's Health
Feb 6, 2023 07:30AM Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023
Dec 12, 2022 08:09AM Dare Bioscience (DARE) Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
Dec 12, 2022 08:00AM Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
Aug 17, 2022 07:31AM Organon (OGN) and Samsung Bioepis Announce FDA Approval of HADLIMA
Aug 17, 2022 07:30AM Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
Jun 30, 2022 08:04AM Dare Bioscience (DARE) Announces Closing of Global License Agreement with Organon to Commercialize XACIATO, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis
Jun 30, 2022 08:00AM Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Ba
Mar 31, 2022 07:02AM Organon (OGN) and Dare (DARE) Enter Agreement to Commercialize XACIATO
Mar 31, 2022 07:00AM Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Va
Jan 5, 2022 06:30AM FDA Accepts Samsung Bioepis’ and Organon’s (OGN) sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
Jan 5, 2022 06:30AM FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
Aug 26, 2021 09:30AM Avestria Ventures Closes Fund I
Jun 15, 2021 07:00AM AtriCure Names Two New Members to the Board of Directors
Jun 3, 2021 06:48AM Merck (MRK) Announces Completion of Organon & Co. (OGN) Spinoff
May 7, 2021 01:05PM Merck (MRK) Declares Record Date and Dividend for the Organon & Co. Spinoff
View More Recent Stories